Aroa Biosurgery (ASX:ARX) said that it expects its fiscal 2026 revenue to be at the upper end of the guidance range of NZ$92 million to NZ$100 million, according to a Tuesday filing with the Australian bourse.
The company also said that it expects its normalized earnings before interest, taxes, depreciation, and amortization for the fiscal year to be at the upper end of the guidance range of NZ$5 million to NZ$8 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.